FIELD: chemistry.
SUBSTANCE: preparation is obtained as an aqueous solution comprising a digoxine-containing component, propylene glycol, citrate buffer solution, ethanol and water. Wherein 0.5-1.2 wt % alcohol solution of digoxin is pre-prepared, maintained under stirring at room temperature for at least 15 minutes, propylene glycol, citrate buffer and water are introduced thereto in amounts providing the following contents of ingredients in the mixture, wt %: 0.5-1.2 wt % alcohol digoxin solution - 5-6.07;. propylene glycol - 8-12; a mixture of citric acid monohydrate and sodium citrate dihydrate, used for preparing the citrate buffer solution - 0.5-0.6; water - the rest, then pH 7.0±0.1 is established, after which the resulting mixture is heated in a closed volume at 170±20°C for at least 20 min.
EFFECT: receiving digoxin preparation with a minimum amount of ethanol, capable of long-term storage at room temperature.
2 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CARDIOVASCULAR HOMOGRAFT (VERSIONS), METHOD FOR PREPARING HOMOGRAFT, HOMOGRAFT TISSUE EXPOSURE MEDIUM (VERSIONS) | 2013 |
|
RU2525197C1 |
| ANESTHETIC LIQUID PHARMACEUTICAL COMPOSITION | 2021 |
|
RU2783438C1 |
| LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION, HAVING NOOTROPIC ACTIVITY | 2018 |
|
RU2703293C1 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AN OPIOID RECEPTOR AGONIST AS ACTIVE INGREDIENT, METHODS OF THEIR PRODUCTION AND THEIR THERAPEUTIC USE | 2018 |
|
RU2795099C2 |
| LIQUID COMPOSITIONS CONTAINING VALSARTAN | 2008 |
|
RU2488393C2 |
| THE COMPOSITION OF FENFLURAMINE, COMPATIBLE WITH A KETOGENIC DIET | 2018 |
|
RU2778848C2 |
| FORMULATIONS OF 2-IMINOBIOTINE AND USE THEREOF | 2011 |
|
RU2627460C2 |
| METHOD AND COMPOSITION FOR STABILISING CELL-FREE NUCLEIC ACIDS AND CELLS | 2018 |
|
RU2764245C2 |
| COMPOSITION, IN STABLE CONDITION, SINGLE-STRANDED NUCLEIC ACID MOLECULE WHICH SUPPRESSES EXPRESSION OF GENE TGF-Β1 | 2016 |
|
RU2714257C2 |
